O-12 NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal
Titel:
O-12 NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal
Auteur:
Morris, V. Ciombor, K. Polite, B. Mukherjee, S. Krauss, J. Shields, A. Aranha, O. Hays, J. Kazmi, S. Weinberg, B. Benson, A. Lieu, C. Iqbal, S. Hochster, H. Xiao, L. Eng, C.